Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452852 | 0.89 | ROCK2 (0.56) | CHEK1SMYD3ROCK2RAB9ANPC1 | |
| SCHEMBL19902696 | 0.83 | NPC1 (0.50) | CHEK1SMYD3ROCK2RAB9ANPC1 | |
| SCHEMBL19902705 | 0.81 | CHRNA7 (0.48) | CHEK1SMYD3ROCK2MAPK14LMNA | |
| SCHEMBL19902369 | 0.80 | ROCK2 (0.46) | CHEK1SMYD3ROCK2NPC1MAPK14 | |
| SCHEMBL19902708 | 0.79 | HPGD (0.48) | SMYD3ROCK2RAB9ANPC1LMNA | |
| SCHEMBL19902622 | 0.78 | MAPK14 (0.54) | CHEK1ROCK2MAPK14KDM4EALDH1A1 | |
| SCHEMBL19902707 | 0.78 | KDM5A (0.49) | CHEK1ROCK2MAPK14KDM4EALDH1A1 | |
| SCHEMBL19902383 | 0.78 | CYP1A2 (0.48) | SMYD3ROCK2RAB9ANPC1MAPK14 | |
| SCHEMBL19902501 | 0.78 | PTGER3 (0.47) | ROCK2MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL19902479 | 0.78 | KHK (0.48) | ROCK2MAPK14KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | CHEK1 956/4885SMYD3 1799/4885ROCK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.